How are we accommodating for the potential for untreated additions when it comes to learning and performance expectations. What are the accountability, legal, and ethical issues?

Permalink Reply by Paul Terlemezian on April 23, 2023 at 3:13pm

2018 Medicare Expands Coverage To Include Performance-Based Diabetes Pre...

How might we broaden the range of learning abilities that we can accommodate - cost effectively, fairly, and ethically?

Permalink Reply by Paul Terlemezian on April 23, 2023 at 3:19pm

2020 Can We Learn From This? 12 Steps For Leaders To Manage Beyond The C...

How many things are we preparing someone to be able to do -simultaneously? How might we increase our willingness to do so?

Permalink Reply by Paul Terlemezian on April 23, 2023 at 3:23pm

2021 Are You Ready For A Prescription For Treatment Tech?

What are the ethics associated with using performance enhancing pharmaceuticals on the job? What are the ethics of health related pharmaceuticals. Are there any differences?

Permalink Reply by Paul Terlemezian on April 23, 2023 at 3:26pm

2022 The I/DD Field – Strategy Issues For The Year Ahead

What fears prevent the effectiveness of learning investments? How can we acknowledge these fears and optimize outcomes?

Permalink Reply by Paul Terlemezian on April 23, 2023 at 3:35pm

2023 The California Juggernaut

How do we know whether or not data objectivity matters? What data matters when it comes to learning investments?

Permalink Reply by Paul Terlemezian on April 23, 2024 at 9:58pm

2024 The Peer Expansion

What is the impact to your decisions and their success of peer insight, approval, or disapproval?